



Docket No.: C1271.70021US02  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Kyle J. Lindstrom *et al.*  
Serial No.: 10/595,103  
Confirmation No.: 2609  
Filed: February 14, 2006  
For: ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED  
IMIDAZOQUINOLINES  
Examiner: Niloofar Rahmani  
Art Unit: 1625

**Certificate of Mailing under 37 CFR § 1.8(a)**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: July 16, 2010

Signature: Amelia S. Lennon (Amelia S. Lennon)

**INFORMATION DISCLOSURE STATEMENT**

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR §§ 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement, pursuant to 37 CFR § 1.114(c), accompanies a Request for Continued Examination (37 CFR § 1.114) submitted herewith. Therefore, no fee or certification is required.

The Applicant would like to bring to the Examiner's attention the following co-pending applications that may contain subject matter related to this application:

<u>Serial No.</u>	<u>Filing Date</u>	<u>Inventor(s)</u>	<u>Docket No.</u>
11/720,862	06-05-2007	Gorden <i>et al.</i>	*C1271.70056US01
11/884,060	05-18-2010	Lundquist <i>et al.</i>	*C1271.70059US01
11/887,525	09-28-2007	Hays <i>et al.</i>	*C1271.70068US01
11/991,663	03-07-2008	Kshirsagar <i>et al.</i>	*C1271.70026US01

\*A copy of this reference is not provided as the Office has waived the requirement under 37 C.F.R. § 1.98(a)(2)(iii) for submitting a copy of a cited U.S. patent application if it is scanned to the Image File Wrapper system and is available on PAIR.

In accordance with 37 CFR § 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR § 1.98(a)(2).


In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR § 1.56(a) exists. In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR § 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency or credit any overpayment in the fees filed, asserted to be filed or which should have been filed herewith to our Deposit Account No. 23/2825, under Docket No. C1271.70021US02.

Dated: July 16, 2010

Respectfully submitted,

By 

C. Hunter Baker, M.D., Ph.D.

Registration Number: 46,533

WOLF, GREENFIELD & SACKS, P.C.

600 Atlantic Avenue

Boston, Massachusetts 02210-2206

617.646.8000